Followers | 832 |
Posts | 119973 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
Sunday, September 06, 2015 3:57:25 PM
If we extrapolate the $1.15M daily rate estimated above over a full quarter, we get $104M, which seems like a reasonable number in relation to Teva’s branded Copaxone sales of $870M during 2Q15.
In 2Q15, MNTA would have received $28.1M in Glatopa revenue from NVS if not for the $9M adjustment to reimburse NVS for pre-launch commercialization expenses. Thus, the operating margin on Glatopa appears to be roughly 80%, and MNTA’s cut is half of that, or 40%.
The $104M estimate for 3Q15 Glatopa sales (above) should therefore equate to approximately $41.5M in 3Q15 Glatopa revenue for MNTA.
p.s. One could estimate 3Q15 Glatopa sales by examining script data and making an assumption regarding average selling price. I haven’t done this, but I’m confident that such an approach would yield a result in the same ballpark as the method used in this post.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM